Zealand Pharma (OTCPK:ZLDP.Y) Update / briefing Transcript

Zealand Pharma Conference Call Summary Company Overview - Company: Zealand Pharma - Product: Petrelintide, an amylin analog - Partnership: Co-development and co-commercialization with Roche Key Industry Insights - Obesity Treatment Landscape: - Obesity is a significant healthcare challenge with a treatment penetration of only 3% to 5% in the U.S. - Current therapies primarily focus on GLP-1 based treatments, which have limitations in long-term treatment persistence and weight maintenance [5][6] Core Findings from Phase 2 ZUPREME-1 Trial - Weight Loss Results: - Petrelintide demonstrated double-digit weight loss, with mean weight loss ranging from 8.7% to 10.7% from baseline over 42 weeks [12][18] - No weight loss plateau was observed, indicating potential for continued weight loss with extended treatment [12][18] - Tolerability and Safety: - Petrelintide exhibited a placebo-like tolerability profile, with low rates of gastrointestinal adverse events [16][17] - No episodes of vomiting were reported in participants treated with the maximally effective dose [17][18] - Approximately 70% of participants on the maximally effective dose did not report any gastrointestinal adverse events [17] - Demographics of Trial Participants: - The trial included 493 participants with a balanced gender distribution, mean body weight of 107 kg, average BMI of 37 kg/m², and mean age of 47 years [11] - Female participants achieved approximately 6 percentage points more weight loss than male participants on a placebo-adjusted basis [14] - Geographic Variations: - Participants from the EU experienced approximately 3 percentage points greater weight loss compared to those from U.S. study sites [15][66] Future Development Plans - Phase 3 Trial Expectations: - Zealand Pharma plans to initiate the Phase 3 program in the second half of 2026, aiming for mid-teen percentage weight loss while maintaining tolerability [19][90] - The design will focus on optimizing conditions to enhance clinical response and long-term treatment adherence [19][90] - Combination Therapy Potential: - There is confidence in Petrelintide's role as both a monotherapy and in combination with CT-388, with the latter expected to enhance treatment outcomes [42][44] Market Positioning and Strategy - Target Market: - Petrelintide aims to redefine the weight management experience, focusing on sustainable weight loss and maintenance rather than just rapid weight loss [20][92] - The product is positioned as a foundational first-choice therapy for individuals living with overweight and obesity, addressing the need for a tolerable treatment option [20][92] Additional Considerations - Regulatory and Competitive Landscape: - The trial design will consider regulatory requirements for diverse populations and previous exposure to weight loss medications [52][62] - The competitive landscape includes multiple amylin programs, with ongoing evaluations of Petrelintide's efficacy and safety compared to other therapies [72][84] Conclusion - Zealand Pharma's Petrelintide shows promise as a leading treatment option in the obesity market, with a strong focus on tolerability and sustained weight loss. The upcoming Phase 3 trials will be crucial in validating its efficacy and establishing its market position against existing therapies.